Sema4 is a patient-centered health intelligence company dedicated to advancing healthcare through data-driven insights. Sema4 is transforming healthcare by applying artificial intelligence (AI) and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. Centrellis®, our innovative health intelligence platform, is enabling us to generate a more complete understanding of disease and wellness and to provide science-driven solutions to the most pressing medical needs. We believe that patients should be treated as partners, and that data should be shared for the benefit of all.
Sema4 was spun out of the Icahn School of Medicine at Mount Sinai in June 2017 with the primary mission of transforming the quality of healthcare for all through mastery of the digital universe of data in partnership with patients and physicians. By closing the gap between the clinical practice of medicine today and the exponentially growing oceans of data, knowledge, and understanding of disease and wellness, Sema4 enables enhanced decision-making by physicians and patients so that they are able to benefit from scientific advances sooner. Sema4 became a public company trading on Nasdaq in July 2021.
Sema4 is accelerating the development and scaling of our innovative health intelligence platform to enable health systems to deliver precision medicine as the standard of care. We envision a future where doctors – and patients – routinely query this platform of algorithms to help determine the most optimal health course journey, personalized to each individual. Biopharma, payers, and population health management companies will also benefit from leveraging our platform, whether identifying and prioritizing the next generation of drug targets for development, stratifying patient populations into risk or disease groups, matching to the most effective treatments, or identifying and enrolling into clinical trials and real-world evidence studies.